Lease of antiviral agents to liver. J Pharm Pharmacol 2006, 58:321-326. 6. Amiji
Lease of antiviral agents to liver. J Pharm Pharmacol 2006, 58:321-326. 6. Amiji MM, Vyas TK, Shah LK: Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov Med 2006, 6:157-162. 7. Baert L, Schueller L, Tardy Y, Macbride D, Klooster GV, Borghys H, Cllessens E, Mooter GVD, Gysegem EV, Remoortee PV, Rosier PWJ: Development of an implantable infusion pump for sustained anti-HIV drug administration. Int J Pharm 2008, 355:38-44. 8. Tronchet JMJ, Seman M: Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase: from the biology of reverse transcription to molecular design. Current Topics in Medicinal Chemistry 2003, 3:1496-511. 9. Maga G, Ubiali D, Salvetti R, Pregnolato M, Spadari S: Selective interaction of the Human immunodeficiency virus type 1 reverse transcriptase non nucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrobial Agents and Chemotherapy 2000, 44:1186-1194.Ramana et al. Journal of Biomedical Science 2010, 17:57 http://www.jbiomedsci.com/content/17/1/Page 9 of10. Currier JS, Havlir DV: Complications of HIV Disease and Antiretroviral Therapy. Top HIV Med 2005, 13:16-23. 11. Chen R, Yokoyama M, Sato H, Reilly C, Mansky LM: Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and non nucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies. J Virology 2005, 79:12045-12057. 12. Petit F, Fromenty B, Owen A, Estaquier J: Mitochondria are sensors for HIV drugs. Trends in PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27324125 Pharmacological Sciences 2005, 26:2558-2264. 13. Fiala M, Murphy T, MacDougall J, Yang W, Luque A: HAART drugs induce mitochondrial damage and intracellular gaps and gp120 causes apoptosis. J Cardiovascular Toxicology 2004, 4:327-337. 14. Kontorinis N, Dieterich D: Hepatotoxicity of Antiretroviral Therapy. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26100631 AIDS Rev 2003, 5:36-43. 15. Hofstede HJMT, Burger DM, Koopmans PP: Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity. Netherlands J Medicine 2003, 61:393-403. 16. Pilon AA, Lum JJ, Dardon JS, Phenix BN, Douglas R, Badley AD: Induction of apoptosis by a nonnucleoside human immunodeficiency virus Type 1 reverse Transcriptase Inhibitor. Antimicrobial Agents and Chemotherapy 2002, 46:2687-2691. 17. Ferrari M: Nanovector therapeutics. Current opinion in chemical biology 2005, 9:343-346. 18. Duncan R: The drawing era of polymer therapeutics. Nature review drug discovery 2003, 3:347-360. 19. Gonzalez de Requena D, Nunez M, Jimenez Nacher I, Soriano V: Liver toxicity caused by nevirapine. AIDS Research Letters 2002, 16:290-291. 20. Betagiri GV, LLY-507 biological activity Deshmukh DV, Gupta RB: Oral sustained- release bioadhesive tablet formulation of didanosine. Drug Dev Ind Pharm 2001, 27:129-136. 21. Govender S, Pillay V, Chetty DJ, Essack SY, Dangor CM, Govender T: Optimisation and characterization of bioadhesive controlled release tetracycline microspheres. Int J Pharm 2005, 306:24-40. 22. Benghuzzi H: Long term sustained delivery of 3′-azido-2′,3′-dideoxy thymidine in vivo by means of HA and TCP delivery devices. Biomed Sci Instrum 2000, 36:343-348. 23. Desormeaux A, Bergeron MG: Liposome as drug delivery system: a strategic approach for the treatment of HIV infection. J Drug target 1998, 6:1-15. 24. Jin SX, Wang DZJ, Wang YZ, Hu HG, Deng YG: Pharmacokinetic and tissue distribution of zidovudine in rats followi.

Leave a Reply